Bryce Point Capital LLC purchased a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 54,358 shares of the biopharmaceutical company's stock, valued at approximately $1,134,000.
A number of other large investors have also modified their holdings of the stock. Charles Schwab Investment Management Inc. raised its holdings in Catalyst Pharmaceuticals by 4.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,167,743 shares of the biopharmaceutical company's stock valued at $23,215,000 after acquiring an additional 50,804 shares in the last quarter. Cerity Partners LLC lifted its position in shares of Catalyst Pharmaceuticals by 31.3% during the 3rd quarter. Cerity Partners LLC now owns 28,733 shares of the biopharmaceutical company's stock worth $571,000 after purchasing an additional 6,847 shares during the last quarter. FMR LLC grew its stake in shares of Catalyst Pharmaceuticals by 24.3% during the third quarter. FMR LLC now owns 98,580 shares of the biopharmaceutical company's stock worth $1,960,000 after purchasing an additional 19,270 shares in the last quarter. Quantbot Technologies LP purchased a new position in Catalyst Pharmaceuticals in the third quarter valued at $151,000. Finally, BNP Paribas Financial Markets lifted its holdings in Catalyst Pharmaceuticals by 206.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 153,250 shares of the biopharmaceutical company's stock worth $3,047,000 after buying an additional 103,186 shares during the last quarter. Hedge funds and other institutional investors own 79.22% of the company's stock.
Catalyst Pharmaceuticals Price Performance
Shares of CPRX stock traded up $0.62 during midday trading on Tuesday, hitting $22.43. The company had a trading volume of 417,941 shares, compared to its average volume of 1,125,742. The stock has a market cap of $2.72 billion, a price-to-earnings ratio of 19.10, a PEG ratio of 3.31 and a beta of 0.79. The company's 50 day simple moving average is $22.76 and its 200 day simple moving average is $21.96. Catalyst Pharmaceuticals, Inc. has a 52-week low of $14.47 and a 52-week high of $26.16.
Insider Buying and Selling
In other news, insider Brian Elsbernd sold 62,975 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares in the company, valued at approximately $4,333,200.72. This trade represents a 25.04 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the sale, the insider now directly owns 68,873 shares in the company, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 11.00% of the company's stock.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on the company. Baird R W raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. Bank of America restated a "buy" rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Robert W. Baird lifted their price target on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research note on Monday, March 3rd. Finally, Stephens reissued an "overweight" rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Seven analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $32.29.
Read Our Latest Stock Analysis on Catalyst Pharmaceuticals
About Catalyst Pharmaceuticals
(
Free Report)
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
Featured Articles
Before you consider Catalyst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalyst Pharmaceuticals wasn't on the list.
While Catalyst Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
